Alembic Pharmaceuticals gains on receiving EU GMP Certificate for Panelav facility

01 Sep 2017 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 522.00, up by 3.50 points or 0.68% from its previous closing of Rs. 518.50 on the BSE.

The scrip opened at Rs. 524.00 and has touched a high and low of Rs. 530.90 and Rs. 518.05 respectively. So far 2,883 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 709.30 on 23-Mar-2017 and a 52 week low of Rs. 492.25 on 27-Jun-2017.

Last one week high and low of the scrip stood at Rs. 530.90 and Rs. 504.60 respectively. The current market cap of the company is Rs. 9,840.53 crore.

The promoters holding in the company stood at 72.68%, while Institutions and Non-Institutions held 14.00% and 13.32% respectively.

Alembic Pharmaceuticals has received EU GMP Certificate for the audit conducted at its Formulation Facility at Panelav from August 8, 2017 to August 10, 2017.

Recently, the pharma major had sold on slump sale basis, its formulations manufacturing facility located at Baddi, Himachal Pradesh to Scott Edil Pharmacia (SEPL), a company engaged in the business of pharmaceuticals products.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.


Alembic Pharma Share Price

865.40 0.65 (0.08%)
16-Dec-2025 11:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1788.20
Dr. Reddys Lab 1275.00
Cipla 1506.60
Zydus Lifesciences 922.05
Lupin 2091.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×